[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05958485":3,"trial-entities:NCT05958485":86,"trial-summary:NCT05958485":90},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":15,"conditions":17,"keywords":19,"study_type":21,"primary_purpose":15,"phases":22,"enrollment_info":23,"interventions":26,"primary_outcomes":27,"secondary_outcomes":34,"sex":35,"minimum_age":36,"maximum_age":15,"healthy_volunteers":37,"eligibility_criteria":38,"std_ages":48,"locations":51,"central_contacts":67,"overall_officials":71,"references":74,"see_also_links":85},"NCT05958485","82196870","A Close Examination of Patient Experiences in Glioblastoma Multiforme Clinical Research","Glioblastoma Multiforme Patients in Clinical Trials: An Examination of Their Clinical Trial Experiences","UNKNOWN","2026-08","2023-07","2023-07-24","2024-08","Power Life Sciences Inc.","INDUSTRY",null,"Clinical research can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative.\n\nThe goal is to identify the obstacles and challenges that prevent participation in glioblastoma multiforme clinical study, as well as the reasons for withdrawal or discontinuation.\n\nInsights gained from this study will ultimately benefit those with glioblastoma multiforme who may be invited to participate in clinical trial in the years to come.",[18],"Glioblastoma Multiforme",[20],"glioblastoma multiforme","OBSERVATIONAL",[],{"count":24,"type":25},500,"ESTIMATED",[],[28,31],{"measure":29,"timeFrame":30},"Rate of patients who decide to enroll in a glioblastoma multiforme clinical study.","3 months",{"measure":32,"timeFrame":33},"Number of glioblastoma multiforme study participants who remain in clinical trial until completion.","12 months",[],"ALL","18 Years",false,{"inclusion":39,"exclusion":43,"raw_text":47},[40,41,42],"Diagnosis of glioblastoma multiforme","No prior treatment for glioblastoma multiforme","Ability to understand and the willingness to sign a written informed consent document.",[44,45,46],"Female patients who are currently pregnant or nursing","Enrolled in another research study","Patients who are currently receiving any other investigational drug.","Inclusion Criteria:\n\n* Diagnosis of glioblastoma multiforme\n* No prior treatment for glioblastoma multiforme\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Female patients who are currently pregnant or nursing\n* Enrolled in another research study\n* Patients who are currently receiving any other investigational drug.",[49,50],"ADULT","OLDER_ADULT",[52],{"facility":53,"city":54,"state":55,"zip":56,"country":57,"contacts":58,"geoPoint":64},"Power Life Sciences","San Francisco","California","94107","United States",[59],{"name":60,"role":61,"phone":62,"email":63},"Michael B Gill","CONTACT","415-900-4227","https:\u002F\u002Fwww.withpower.com\u002Fcontact-us@withpower.com",{"lat":65,"lon":66},37.77493,-122.41942,[68],{"name":60,"role":61,"phone":69,"email":70},"4159004227","bask@withpower.com",[72],{"name":60,"affiliation":13,"role":73},"STUDY_DIRECTOR",[75,79,82],{"pmid":76,"type":77,"citation":78},"24004722","BACKGROUND","Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kosteljanetz M, Poulsen HS. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC Cancer. 2013 Sep 3;13:402. doi: 10.1186\u002F1471-2407-13-402.",{"pmid":80,"type":77,"citation":81},"33486440","Tosoni A, Gatto L, Franceschi E, Di Nunno V, Lodi R, Mura A, Di Battista M, Bartolini S, Brandes AA. Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. Eur J Cancer. 2021 Mar;145:171-178. doi: 10.1016\u002Fj.ejca.2020.12.027. Epub 2021 Jan 22.",{"pmid":83,"type":77,"citation":84},"36309895","Ruda R, Bruno F, Pellerino A, Pronello E, Palmiero R, Bertero L, Crasto S, Polo V, Vitaliani R, Trincia E, Interno V, Porta C, Soffietti R. Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy? J Neurooncol. 2022 Nov;160(2):389-402. doi: 10.1007\u002Fs11060-022-04155-9. Epub 2022 Oct 30.",[],{"nct_id":4,"conditions":87,"biomarkers":89},[88],"Glioblastoma",[],{"nct_id":4,"found":91,"summary":92,"prompt_version":102},true,{"design":93,"status":94,"heading":95,"summary":96,"follow_up":97,"word_count":98,"commitments":99,"compensation":100,"drugs_mentioned":101},"This is an observational study with a planned enrollment of 500 participants. It is not testing a specific intervention or drug.","completed","Understanding Patient Experiences in Glioblastoma Clinical Research","This observational study aims to understand why people with glioblastoma multiforme (a type of brain cancer) choose to join or leave clinical trials. Researchers want to identify what helps or hinders participation, and the reasons for stopping a trial early. This study doesn't test a new treatment; instead, it gathers information from 500 participants to improve future clinical trials for glioblastoma patients. You could be eligible if you have a glioblastoma diagnosis, haven't had prior treatment for it, and are able to give informed consent. The study will look at how many people enroll within 3 months and how many stay until the end of a trial, measured at 12 months.","The study measures how many participants remain in a clinical trial until completion at 12 months.",111,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]